F. Hertwig

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

This paper shows that high MYCN levels in neuroblastoma reduce L1CAM expression, limiting CAR T cell efficacy, and that inhibiting MYCN with MLN8237 restores L1CAM and enhances CAR T cell activity.

Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance

This study identifies feedback-mediated resistance to MEK inhibitors in neuroblastoma and shows that combining MEK with RAF or IGFR inhibitors can overcome resistance.

PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumors.

This study identifies PPM1D as an oncogene and therapeutic target in neuroblastoma by showing its role in p53 inactivation and tumor growth.

Enhancer hijacking determines intra- and extrachromosomal circular MYCN amplicon architecture in neuroblastoma

The paper identifies two distinct MYCN amplicon structures in neuroblastoma, showing how enhancer hijacking compensates for loss of local regulatory elements.